Ceacam5 antibody-drug conjugate for use in cancer therapy

TW202637220APending Publication Date: 2026-09-16SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114140065
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-17
Filing Date
2025-10-16
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001076327_001
    Figure TWG2TA001076327_001
  • Figure TWG2TA001076327_002
    Figure TWG2TA001076327_002
  • Figure TWG2TA001076327_003
    Figure TWG2TA001076327_003
Patent Text Reader

Abstract

Provided are compositions and methods to treat cancers that express CEACAM5. Certain aspects of the disclosure relate to monotherapy with immunoconjugates comprising an anti-CEACAM5 antibody. Other aspects of the disclosure relate to combination therapies with immunoconjugates comprising an anti-CEACAM5 antibody and a nucleoside metabolic inhibitor. The disclosed compositions are used to treat pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art